Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study)

Epilepsia

Volumn 49, Issue 3, 2008, Pages 410-417

  Tompson, Debra J ^a   Ali, Imran ^b   Oliver Willwong, Ruth ^a   Job, Sarah ^a   Zhu, Li ^c   Lemme, Francesca ^d   Hammer, Anne E ^e   Vuong, Alain ^e   Messenheimer, John A ^e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c ICON Development Solutions   (United States)

^d GSK   (Italy)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Epilepsy; Extended release; Immediate release; Lamotrigine; Pharmacokinetics; Safety

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ABRASION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; EPILEPSY; EXTENDED RELEASE FORMULATION; FEMALE; HEADACHE; HUMAN; IMMEDIATE RELEASE FORMULATION; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; STEADY STATE; SYNCOPE; TIMED DRUG RELEASE; TREMOR; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HEADACHE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PATIENT SATISFACTION; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; VOMITING;

EID: 39749110172     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01274.x     Document Type: Article

References (20)

1. Almeida AM, Falcao AC, Sales F, Baldeiras I, Rocha MJ, Caramona MM 2006) Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. Eur J Clin Pharmacol 62 : 737 742.
2. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG, de Korte RA, Meijer JW, Meinardi H, Miller AA, Overweg J, Peck AW, van Wieringen A, Yuen WC 1986) Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27 : 248 254.
3. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA 2005) Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65 : 1737 1743.
4. Claxton AJ, Cramer J, Pierce C 2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 : 1296 1310.
5. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW 1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal man. Clin Pharmacol Ther 42 : 535 541.
6. Dulac O, Kaminska A 1997) Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 12 (suppl 1 S23 S28.
7. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M 2003) Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res 57 : 85 93.
8. Goa KL, Ross SR, Chrisp P 1993) Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46 : 152 176.
9. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A 1987) Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1 : 194 220.
10. Johannessen SI 2005) Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. Ther Drug Monit 27 : 710 713.
11. ® (package insert) 2006) Research Triangle Park. GlaxoSmithKline.
12. Magdalou J, Herber R, Bidault R, Siest G 1992) In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 260 : 1166 1173.
13. May TW, Rambeck B, Jurgens U 1996) Serum concentrations of lamotrigine in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 18 : 523 531.
14. Morris RG, Black AB, Lam E, Westley IS 2000) Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit 22 : 656 660.
15. Naritoku DK, Warnock CR, Messenheimer JA, Borgohain R, Evers S, Guekht AB, Karlov VA, Lee BI, Ríos-Pohl L. Double-blind, randomized, placebo-controlled trial of lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology (In press).
16. Pellock JM 1994) The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 44 (suppl 8 29 35.
17. Rambeck B, Wolf P 1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25 : 433 443.
18. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO 2006) In vitro characterization of lamotrigine n2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metabol Disposition 34 : 1055 1062.
19. Weintraub D, Buchsbaum R, Resor SR Jr., Hirsch LJ 2005) Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 62 : 1432 1436.
20. Yuen AWC, Land G, Weatherley BC, Peck AW 1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 33 : 511 513.